The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a comparable https://agnescrvi139145.widblog.com/93560958/retatrutide-vs-tirzepatide-a-comparative-analysis